Biogen Inc. / Neomorph Inc.

Alzheimer's Disease, Rare Neurological Diseases, and Immunology (Molecular Glue Platform)

60M US cases/yr · $180.0B Global CNS + Immunology Therapeutics Market

Disease Overview

The Biogen-Neomorph collaboration targets undisclosed priority targets across Alzheimer's disease, rare neurological diseases, and immunological diseases. Alzheimer's disease affects ~6.7 million US adults with expected growth to ~14 million by 2060, driven by accumulation of amyloid-beta plaques and hyperphosphorylated tau neurofibrillary tangles producing synaptic dysfunction, neuroinflammation, and neuronal death. Recent anti-amyloid antibody approvals (Leqembi/lecanemab from Biogen-Eisai, Kisunla/donanemab from Eli Lilly) have validated amyloid-lowering as disease-modifying, but efficacy is modest and ARIA safety constrains use, motivating pursuit of tau-directed and neuroinflammation modalities. Rare neurological diseases include spinal muscular atrophy, amyotrophic lateral sclerosis (~30,000 US), Huntington's disease (~30,000), Friedreich ataxia, and hundreds of monogenic neurogenetic disorders with aggregation-prone or loss-of-function proteins. Immunology covers rheumatoid arthritis, lupus, IBD, psoriasis, atopic dermatitis, and asthma, collectively affecting over 50 million Americans. Many high-value CNS and immunology targets are transcription factors (e.g., STAT5b, IRF5), scaffolding proteins, or aggregation-prone proteins historically undruggable by conventional small molecules. Molecular glue degraders redirect E3 ubiquitin ligases to catalytically degrade these proteins, offering potential advantages over antibodies (oral administration, CNS penetration, substoichiometric activity).

Competitive Landscape

The competitive landscape for molecular glue degraders in CNS and immunology is nascent but expanding. Molecular glue platform companies include Neomorph (Novo Nordisk, Biogen partnerships totaling nearly $3B biobucks in 2024), Monte Rosa Therapeutics (QuEEN platform; Novartis partnership for VAV1 and others; MRT-6160 VAV1 for immunology), C4 Therapeutics (Roche partnership), Kymera Therapeutics (KT-474 IRAK4 for HS and AD partnered with Sanofi; KT-621 STAT6 for atopic dermatitis partnered with Sanofi), Arvinas (Pfizer partnership on vepdegestrant), Foghorn Therapeutics (Eli Lilly partnership), Nurix Therapeutics (Gilead BTK degrader NX-5948; Sanofi STAT6 degrader), Plexium, Captor, Proxygen (Boehringer), and Vividion (Bayer/Roivant). In Alzheimer's disease, approved disease-modifying therapies Leqembi (lecanemab, Biogen/Eisai) and Kisunla (donanemab, Eli Lilly) are anti-amyloid antibodies; emerging tau-directed agents include BIIB080 (tau ASO, Biogen/Ionis), E2814 (tau antibody, Eisai), JNJ-63733657/posdinemab (Johnson & Johnson), and bepranemab (UCB/Roche). Biogen's broader neurology franchise includes Leqembi, Spinraza (nusinersen SMA ASO), Qalsody (tofersen SOD1-ALS), Zurzuvae (zuranolone PPD), Vumerity and Tysabri (MS), contextualizing the platform partnership as a move beyond amyloid and existing ASO/antibody modalities.